StockData
Royalty Pharma plc logo

Royalty Pharma plc (RPRX) stock

RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/3051% above fair value
$68.67−0.01 (-0.01%)

Close on Nov 18, 2026Market cap $39.49BP/E 39.0Yield –

Royalty Pharma pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Royalty Pharma's pe ratio was 39.8× on Nov 11, 2026, against 24.6× a year earlier. Over the last 5 years it ranged from 10.9× to 360.3×, with a median of 28.1×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202639.8×+16.1
2025Dec 31, 202523.7×+12.5
2024Dec 31, 202411.2×−60.8
2023Dec 29, 202372.0×+38.0
2022Dec 30, 202234.1×+13.4
2021Dec 31, 202120.6×–

More Royalty Pharma figures

See a number that looks wrong?